We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
Read MoreHide Full Article
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $56.42, moving +1.58% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 1.05% for the day. At the same time, the Dow added 0.69%, and the tech-heavy Nasdaq gained 1.64%.
Coming into today, shares of the company had gained 19.62% in the past month. In that same time, the Medical sector gained 0.31%, while the S&P 500 gained 8.59%.
The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. The company is forecasted to report an EPS of -$1.14, showcasing a 27.85% upward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $8.39 million, indicating a 864.14% upward movement from the same quarter last year.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$4.93 per share and revenue of $35.78 million. These results would represent year-over-year changes of +23.8% and +919.38%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.46% lower. Right now, CRISPR Therapeutics AG possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 93, finds itself in the top 39% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
CRISPR Therapeutics AG (CRSP - Free Report) closed the most recent trading day at $56.42, moving +1.58% from the previous trading session. The stock exceeded the S&P 500, which registered a gain of 1.05% for the day. At the same time, the Dow added 0.69%, and the tech-heavy Nasdaq gained 1.64%.
Coming into today, shares of the company had gained 19.62% in the past month. In that same time, the Medical sector gained 0.31%, while the S&P 500 gained 8.59%.
The investment community will be closely monitoring the performance of CRISPR Therapeutics AG in its forthcoming earnings report. The company is forecasted to report an EPS of -$1.14, showcasing a 27.85% upward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $8.39 million, indicating a 864.14% upward movement from the same quarter last year.
CRSP's full-year Zacks Consensus Estimates are calling for earnings of -$4.93 per share and revenue of $35.78 million. These results would represent year-over-year changes of +23.8% and +919.38%, respectively.
It's also important for investors to be aware of any recent modifications to analyst estimates for CRISPR Therapeutics AG. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the business and profitability.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1.46% lower. Right now, CRISPR Therapeutics AG possesses a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 93, finds itself in the top 39% echelons of all 250+ industries.
The Zacks Industry Rank evaluates the power of our distinct industry groups by determining the average Zacks Rank of the individual stocks forming the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.